A Phase 3 interventional study of Octreotide capsules in Acromegaly, sponsored by Chiasma, Inc.. Completed at 36 sites in 13 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-17.
Sponsored by Chiasma, Inc. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.
Among the 25 studies testing octreotide in Acromegaly, this one is the 2nd largest by enrollment, is one of 2 that started in 2012, is one of 12 in phase 3, and was the 15th registered.
202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
Browse Acromegaly studies →1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Ages 18–80
Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 43 across 115 interventional studies indexed under Acromegaly.
Median enrollment 56 across the 25 interventional studies. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chiasma, Inc., one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
Chiasma, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Chiesi Farmaceutici S.p.A. has 3 studies filed under Acromegaly — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing octreotide in Acromegaly, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly.
The study consisted of 2 periods, a Core Treatment Period of up to 7 months and an optional Extension Treatment Period of up to 6 months, for a total study duration of up to 13 months. The Core Treatment Period consisted of 2 phases, a Dose Escalation Phase of at least 2 months to identify the therapeutic dose for each study participant and a Fixed Dose Phase of 2 to 5 months during which the therapeutic dose was maintained.
Participants were eligible to enter the Fixed Dose Phase of the Core Treatment Period if they were clinically and biochemically controlled. The same criteria were used to allow entry into the voluntary 6-month Extension Treatment Period.
The Core Treatment Period of the study was completed if the participant had at least 2 months of treatment in the Fixed Dose Phase and a total treatment duration of at least 7 months. Participants who elected to continue into the Extension Treatment Period maintained their therapeutic dose during this period. At the end of the study (after the last dose of MYCAPSSA in either the Core Treatment Period or the Extension Treatment Period), there was a 2-week follow-up period for safety assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
Drug: Octreotide capsules
Octreotide was provided in hard gelatin capsules.
Also known as: MYCAPSSA™, Formerly known as Octreolin™
Percentage of Responders at the End of the Core Treatment Period
A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
Time frame: End of the core treatment period (up to 7 months)
Percentage of Responders at the End of the Extension Treatment Period
A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
Time frame: End of the extension treatment period (up to 13 months)
Percentage of Participants With Specified IGF-1 and GH Concentrations at Baseline and at the End of the Core Treatment Period
Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at Baseline and at the end of the core treatment period (ECTP): IGF-1 \< 1.3 times the upper limit of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
Time frame: Baseline and the end of the core treatment period (up to 7 months)
Maintenance of Response During the Fixed Dose Phase of the Core Treatment Period
Maintenance of response during the fixed dose phase of the core treatment period was defined as the percentage of participants with an insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal at the beginning of the fixed dose phase of the core treatment period and at the end of the core treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.
Time frame: Beginning of the fixed dose phase of the core treatment period and the end of the core treatment period (up to 7 months)
Percentage of Participants With Specified IGF-1 and GH Concentrations at the Beginning and at the End of the Extension Treatment Period
Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at the beginning (BETP) and at the end (EETP) of the extension treatment period: IGF-1 \< 1.3 times the upper level of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
Time frame: Beginning and the end of the extension treatment period (up to 6 months)
Maintenance of Response During the Extension Treatment Period
Maintenance of an insulin-like growth factor-1 (IGF-1) response during the extension treatment period was defined as the percentage of participants with an IGF-1 concentration \< 1.3 times the upper limit of normal at the beginning of the extension treatment period and at the end of the extension treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.
Time frame: Beginning of the extension treatment period and the end of the extension treatment period (up to 13 months)
Percentage of Participants With Improved or Maintained Acromegaly Symptoms at the End of the Extension Treatment Period
The severity (absent, mild, moderate, severe) of the 5 acromegaly symptoms headache, perspiration, asthenia, swelling of extremities, and joint pain was assessed at Baseline and at the end of the extension treatment period. The percentage of participants with improved or maintained (no change) acromegaly symptoms from Baseline at the end of the extension treatment period is reported.
Time frame: Baseline and the end of the extension treatment period (up to 13 months)
Percentage of Participants With ≥ 1, 2, or 3 Acromegaly Symptoms at Baseline and at the End of the Extension Treatment Period
Reported is the percentage of participants who had ≥ 1, 2, or 3 of the 5 symptoms of acromegaly (headaches, perspiration, asthenia, swelling of extremities, or joint pain) of any severity (mild, moderate, or severe). This was a post hoc analysis.
Time frame: Baseline and the end of the extension treatment period (up to 13 months)
| Milestone | Octreotide Capsules |
|---|---|
| Started | 155 |
| Completed | 102 |
| Not completed | 53 |
| Withdrew: Treatment failure | 24 |
| Withdrew: Adverse event | 21 |
| Withdrew: Patient request | 5 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Sponsor request | 1 |
| Milestone | Octreotide Capsules |
|---|---|
| Started | 88 |
| Completed | 82 |
| Not completed | 6 |
| Withdrew: Adverse event | 2 |
| Withdrew: Treatment failure | 2 |
| Withdrew: Patient request | 2 |
A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
| Percentage of responders | Octreotide 40 mg | Octreotide 60 mg | Octreotide 80 mg | Octreotide 40, 60, or 80 mg - All Participants |
|---|---|---|---|---|
| Percentage of Responders at the End of the Core Treatment Period | 86.9 (83.0 to 98.1) | 66.7 (48.2 to 82.0) | 40.4 (27.6 to 54.2) | 64.9 (58.4 to 74.2) |
A responder was defined as a participant with a serum insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal (adjusted for age and gender) and a growth hormone (GH) concentration \< 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
| Percentage of responders | Octreotide Capsules |
|---|---|
| Percentage of Responders at the End of the Extension Treatment Period | 78.4 (68.4 to 86.5) |
Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at Baseline and at the end of the core treatment period (ECTP): IGF-1 \< 1.3 times the upper limit of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
| Percentage of participants | Octreotide Capsules |
|---|---|
| IGF-1 < 1.3 & GH < 5.0: Baseline | 91.4 |
| IGF-1 < 1.3 & GH < 5.0: ECTP | 65.6 |
| IGF-1 < 1.3 & GH < 1.0: Baseline | 62.9 |
| IGF-1 < 1.3 & GH < 1.0: ECTP | 53.0 |
| IGF-1 ≤ 1.0 & GH < 5.0: Baseline | 63.6 |
| IGF-1 ≤ 1.0 & GH < 5.0: ECTP | 35.8 |
| IGF-1 ≤ 1.0 & GH < 2.5: Baseline | 61.6 |
| IGF-1 ≤ 1.0 & GH < 2.5: ECTP | 35.8 |
| IGF-1 ≤ 1.0 & GH < 1.0: Baseline | 43.0 |
| IGF-1 ≤ 1.0 & GH < 1.0: ECTP | 31.8 |
| IGF-1 < 1.3: Baseline | 91.4 |
| IGF-1 < 1.3: ECTP | 66.9 |
| IGF-1 ≤ 1.0: Baseline | 63.6 |
| IGF-1 ≤ 1.0: ECTP | 37.1 |
| GH < 5.0: Baseline | 100.0 |
| GH < 5.0: ECTP | 97.4 |
| GH < 2.5: Baseline | 96.0 |
| GH < 2.5: ECTP | 94.7 |
| GH < 1.0: Baseline | 66.2 |
| GH < 1.0: ECTP | 77.5 |
| IGF-1 ≥ 1.3 & GH < 2.5: Baseline | 7.3 |
| IGF-1 ≥ 1.3 & GH < 2.5: ECTP | 29.8 |
| IGF-1 < 1.3 & GH ≥ 2.5: Baseline | 2.6 |
| IGF-1 < 1.3 & GH ≥ 2.5: ECTP | 0.7 |
| IGF-1 ≥ 1.3 & GH ≥ 2.5: Baseline | 1.3 |
| IGF-1 ≥ 1.3 & GH ≥ 2.5: ECTP | 2.0 |
Maintenance of response during the fixed dose phase of the core treatment period was defined as the percentage of participants with an insulin-like growth factor-1 (IGF-1) concentration \< 1.3 times the upper limit of normal at the beginning of the fixed dose phase of the core treatment period and at the end of the core treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.
| Percentage of participants | Octreotide Capsules |
|---|---|
| Beginning of the FDP of the CTP | 82.7 |
| End of the CTP | 80.0 |
Percentage of participants with the following serum insulin-like growth factor-1 (IGF-1) and growth hormone (GH) concentrations at the beginning (BETP) and at the end (EETP) of the extension treatment period: IGF-1 \< 1.3 times the upper level of normal (ULN) and GH \< 5.0 ng/mL, IGF-1 \< 1.3 times ULN and GH \< 1.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 5.0 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 2.5 ng/mL, IGF-1 ≤ 1.0 times ULN and GH \< 1.0 ng/mL, IGF-1 \< 1.3 times ULN, IGF-1 ≤ 1.0 times ULN, GH \< 5.0 ng/mL, GH \< 2.5 ng/mL, GH \< 1.0 ng/mL, IGF-1 ≥ 1.3 times ULN and GH \< 2.5 ng/mL, IGF-1 \< 1.3 times ULN and GH ≥ 2.5 ng/mL, and IGF-1 ≥ 1.3 times ULN and GH ≥ 2.5 ng/mL. The growth hormone concentration was the mean of 5 fasted GH serum concentrations collected at 30 minute intervals for 2 hours, 2 to 4 hours post-octreotide dose. IGF-1 concentration was determined in serum samples taken at the same visits GH concentration was assessed.
| Percentage of participants | Octreotide Capsules |
|---|---|
| IGF-1 < 1.3 & GH < 5.0: BETP | 84.1 |
| IGF-1 < 1.3 & GH < 5.0: EETP | 79.5 |
| IGF-1 < 1.3 & GH < 1.0: BETP | 69.3 |
| IGF-1 < 1.3 & GH < 1.0: EETP | 68.2 |
| IGF-1 ≤ 1.0 & GH < 5.0: BETP | 48.9 |
| IGF-1 ≤ 1.0 & GH < 5.0: EETP | 50.0 |
| IGF-1 ≤ 1.0 & GH < 2.5: BETP | 48.9 |
| IGF-1 ≤ 1.0 & GH < 2.5: EETP | 50.0 |
| IGF-1 ≤ 1.0 & GH < 1.0: BETP | 42.0 |
| IGF-1 ≤ 1.0 & GH < 1.0: EETP | 44.3 |
| IGF-1 < 1.3: BETP | 84.1 |
| IGF-1 < 1.3: EETP | 79.5 |
| IGF-1 ≤ 1.0: BETP | 48.9 |
| IGF-1 ≤ 1.0: EETP | 50.0 |
| GH < 5.0: BETP | 100.0 |
| GH < 5.0: EETP | 97.7 |
| GH < 2.5: BETP | 98.9 |
| GH < 2.5: EETP | 95.5 |
| GH < 1.0: BETP | 83.0 |
| GH < 1.0: EETP | 83.0 |
| IGF-1 ≥ 1.3 & GH < 2.5: BETP | 14.8 |
| IGF-1 ≥ 1.3 & GH < 2.5: EETP | 17.0 |
| IGF-1 < 1.3 & GH ≥ 2.5: BETP | 0.0 |
| IGF-1 < 1.3 & GH ≥ 2.5: EETP | 1.1 |
| IGF-1 ≥ 1.3 & GH ≥ 2.5: BETP | 1.1 |
| IGF-1 ≥ 1.3 & GH ≥ 2.5: EETP | 3.4 |
Maintenance of an insulin-like growth factor-1 (IGF-1) response during the extension treatment period was defined as the percentage of participants with an IGF-1 concentration \< 1.3 times the upper limit of normal at the beginning of the extension treatment period and at the end of the extension treatment period. IGF-1 concentration was determined in serum samples taken at the same visits growth hormone concentration was assessed.
| Percentage of participants | Octreotide Capsules |
|---|---|
| Maintenance of Response During the Extension Treatment Period | 87.8 (78.2 to 94.3) |
The severity (absent, mild, moderate, severe) of the 5 acromegaly symptoms headache, perspiration, asthenia, swelling of extremities, and joint pain was assessed at Baseline and at the end of the extension treatment period. The percentage of participants with improved or maintained (no change) acromegaly symptoms from Baseline at the end of the extension treatment period is reported.
| Percentage of participants | Octreotide Capsules |
|---|---|
| Maintained | 27 (18.3 to 37.8) |
| Improved | 57 (45.8 to 67.3) |
Reported is the percentage of participants who had ≥ 1, 2, or 3 of the 5 symptoms of acromegaly (headaches, perspiration, asthenia, swelling of extremities, or joint pain) of any severity (mild, moderate, or severe). This was a post hoc analysis.
| Percentage of participants | Octreotide Capsules |
|---|---|
| 1 Symptom - Baseline | 78 |
| 1 Symptom - End of the extension treatment period | 65 |
| 2 Symptoms - Baseline | 61 |
| 2 Symptoms - End of the extension treatment period | 43 |
| 3 Symptoms - Baseline | 43 |
| 3 Symptoms - End of the extension treatment period | 25 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Octreotide 40 mg | 1/155 (0.6%) | 9/155 (5.8%) | 103/155 (66.5%) |
| Octreotide 60 mg | 0/91 (0%) | 7/91 (7.7%) | 51/91 (56%) |
| Octreotide 80 mg | 1/58 (1.7%) | 8/58 (13.8%) | 31/58 (53.4%) |
| Event | Octreotide 40 mg | Octreotide 60 mg | Octreotide 80 mg |
|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/155 | 1/91 | 1/58 |
| Cholecystitis acuteHepatobiliary disorders | 0/155 | 0/91 | 1/58 |
| HeadacheNervous system disorders | 0/155 | 0/91 | 1/58 |
| Herpes simplex ophthalmicInfections and infestations | 0/155 | 0/91 | 1/58 |
| Urinary tract infectionInfections and infestations | 0/155 | 0/91 | 1/58 |
| MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/155 | 0/91 | 1/58 |
| Acute myocardial infarctionCardiac disorders | 0/155 | 0/91 | 1/58 |
| Intervertebral disc protusionMusculoskeletal and connective tissue disorders | 0/155 | 0/91 | 1/58 |
| TinnitusEar and labyrinth disorders | 0/155 | 0/91 | 1/58 |
| VertigoEar and labyrinth disorders | 0/155 | 0/91 | 1/58 |
| Event | Octreotide 40 mg | Octreotide 60 mg | Octreotide 80 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 44/155 | 18/91 | 20/58 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 25/155 | 20/91 | 11/58 |
| NauseaGastrointestinal disorders | 30/155 | 14/91 | 6/58 |
| AstheniaGeneral disorders | 27/155 | 11/91 | 8/58 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 23/155 | 9/91 | 6/58 |
| Oedema peripheralGeneral disorders | 19/155 | 8/91 | 5/58 |
| DiarrhoeaGastrointestinal disorders | 18/155 | 11/91 | 4/58 |
| NasopharyngitisInfections and infestations | 5/155 | 4/91 | 5/58 |
| Abdominal painGastrointestinal disorders | 5/155 | 7/91 | 1/58 |
| DyspepsiaGastrointestinal disorders | 11/155 | 2/91 | 1/58 |
Safety population: All participants enrolled in the study who received any amount of the study drug.
| Age, Continuous(Years) | Octreotide Capsules |
|---|---|
| Mean | 54.2 ± 11.54 |
| Sex: Female, Male(Participants) | Octreotide Capsules |
|---|---|
| Female | 88 |
| Male | 67 |
| Ethnicity (NIH/OMB)(Participants) | Octreotide Capsules |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 135 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Octreotide Capsules |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 137 |
| More than one race | 0 |
| Unknown or Not Reported | 16 |
The record gives a start of Mar 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Octreotide